Breaking Down Global Health Limited Financial Health: Key Insights for Investors

Investors tracking Medanta will want to dig into a quarter that delivered total income of ₹10,513 million (up 19.1% YoY) alongside a sharp net profit of ₹1,590 million (a 49.6% YoY jump) and an improved EBITDA margin of 24.3%, while occupied bed days rose 13.3% to yield a 63.2% occupancy rate; add a trailing twelve months EBITDA of ₹9.91 billion (24% margin) and a net cash position of ₹6.93 billion backed by ₹12.2 billion in cash even as gross debt edged to ₹5.27 billion, and you get a company with a market cap of ₹33,868 crore and a share price of ₹1,255 (analysts targeting ₹1,435) where valuation metrics - P/E 66.8, EV/EBITDA 38.0 and P/S 7.87 - sit against risks like a negative free cash flow of ₹119 million to Sept 2025 and rising debt but also clear growth levers (plans for 1,300+ new beds, a 550-bed Noida project and CGHS rate revisions expected to lift ARPOB by 2.5-3.5%); read on for a line-by-line breakdown of revenue trends, profitability dynamics, liquidity and solvency, valuation context and the key risks and opportunities that should shape your investment view

Global Health Limited (MEDANTA.NS) - Revenue Analysis

• Total income for Q1 FY2026: ₹10,513 million (19.1% YoY)
• EBITDA for Q1 FY2026: ₹2,553 million (up 22.6% YoY); EBITDA margin: 24.3%
• Net profit for Q1 FY2026: ₹1,590 million (up 49.6% YoY); Net margin: 15.1%
• Occupied bed days increased 13.3% YoY; occupancy rate: 63.2%
• Q2 FY2026 revenue growth: 14.91% YoY
• Analyst consensus: FY2026 revenue growth forecast ~14%

Global Health Limited (MEDANTA.NS) Profitability Metrics

Global Health Limited (MEDANTA.NS) has shown improved profitability across recent reporting periods, driven by operating leverage, revenue growth in core services, and cost controls that boosted margins and bottom-line performance.

• EBITDA margin: improved to 24.3% in Q1 FY2026 from 23.6% in Q1 FY2025.
• Net profit margin: 15.1% in Q1 FY2026, a significant year-on-year uplift.
• ROE (forecast): 16.8% in three years, signaling strong capital efficiency expectations.
• Q2 FY2026 net profit growth: 21.09% year-over-year increase.

Key trailing metrics provide a stable view of recent performance:

Investors reviewing profitability should consider operational drivers behind these numbers-case mix, occupancy, average revenue per case, cost of consumables and staff expenses-which collectively have pushed EBITDA and net margins higher. For deeper investor context and shareholder trends, see: Exploring Global Health Limited Investor Profile: Who's Buying and Why?

Global Health Limited (MEDANTA.NS) - Debt vs. Equity Structure

• Total debt: ₹5.27 billion (up from ₹3.02 billion a year ago)
• Cash reserves: ₹12.2 billion
• Net cash position: ₹6.93 billion (Cash minus Debt)
• Debt-to-equity ratio: 0.21
• Total liabilities: ₹13.79 billion
• Current (due within one year) liabilities: ₹7.21 billion
• Shareholders' equity: ₹33.88 billion
• Historic net cash milestone: net debt-free with a net cash surplus of ₹4.69 billion at end-March 2023

• Leverage profile: With a debt-to-equity of 0.21, Global Health Limited sits well below typical industry caution thresholds, indicating conservative debt usage relative to its equity base.
• Liquidity cushion: Cash reserves of ₹12.2 billion provide a significant buffer against the ₹7.21 billion of current liabilities, supporting short-term flexibility and operational continuity.
• Recent debt trend: Debt increased from ₹3.02 billion to ₹5.27 billion year-on-year; however, the company remains net cash positive, implying any incremental borrowings have not impaired overall liquidity.

Global Health Limited (MEDANTA.NS) - Liquidity and Solvency

• Operating cash flow (FY2025): ₹6.0 billion (up 1.9% YoY).
• Free cash flow (TTM): ₹1.07 billion; operating cash flow to net income ratio: 1.17.
• Current assets: ₹15.0 billion (up 2% YoY); current liabilities: ₹6.0 billion (up 0.2% YoY).
• Cash + receivables exceed current liabilities; net cash position: ₹6.93 billion.
• Positive operating cash flow has consistently covered net income, indicating cash quality and earnings convertibility.

• Coverage and cushion: With cash and receivables exceeding current liabilities and a net cash position near ₹7 billion, the company has a strong short-term liquidity cushion for working capital, debt servicing and discretionary investment.
• Cash quality: Ongoing positive operating cash flows and an OCF-to-net-income ratio >1 indicate earnings are being converted to cash rather than driven by non-cash items.

Global Health Limited (MEDANTA.NS) - Valuation Analysis

• Price-to-Sales (P/S) FY2025: 7.87 (down from 8.12 in FY2024; a 3.07% decline), indicating slightly improved revenue-based valuation.
• Price per share: ₹1,255 (as of November 7, 2025).
• Market capitalization: ₹33,868 crore.
• Analyst consensus price target: ₹1,435 (≈12% upside from current price).
• Price-to-Earnings (P/E): 66.8, signaling high investor expectations for earnings growth.
• Enterprise Value (EV): ₹352.65 billion with EV/EBITDA: 38.0, implying rich valuation on operating-profit basis.

• Interpretation: the drop in P/S (-3.07%) provides modest valuation relief, but elevated P/E and EV/EBITDA show the stock still commands a high multiple that requires sustained margin and revenue growth to justify current prices.
• Investor action points: compare these multiples to peers, stress-test earnings trajectory, and review balance-sheet leverage given EV magnitude.

Global Health Limited (MEDANTA.NS) Risk Factors

• Negative free cash flow: the company reported a negative free cash flow of ₹119 million for the year to September 2025, constraining internal funding for growth and dividends.
• Accrual vs cash earnings: an accrual ratio of 0.21 indicates that accounting (statutory) profit exceeded cash generation-free cash flow covered only part of reported profits.
• Capital expenditure funding risk: fluctuations in free cash flow may impact the company's ability to fund capital expenditures or require external financing at potentially higher cost.
• Valuation premium: the stock's high P/E ratio suggests the market is pricing in significant future growth; any slowdown in operational performance or growth realization could trigger sharp re-rating.
• Rising leverage: debt levels have increased, which could reduce financial flexibility, raise interest burden and amplify vulnerability to cash-flow shortfalls.
• Market sentiment sensitivity: the company's valuation is likely sensitive to changes in investor sentiment and broader market conditions, increasing share price volatility risk.

• Near-term monitoring priorities: quarterly free cash flow trends, interest coverage and debt maturities, capex plans and progress versus guidance, and any changes in revenue growth that justify the current valuation.
• Trigger events that could amplify risk: a sustained cash flow deficit, rising borrowing costs, missed growth targets, or a sector-wide reassessment of high-P/E healthcare names.

Global Health Limited (MEDANTA.NS) - Growth Opportunities

• Planned bed additions: the company intends to add over 1,300 beds across its network in the next couple of years, materially expanding inpatient capacity and throughput.
• Major greenfield expansion: a 550-bed super‑specialty hospital in Noida is a flagship project within the build-out plan.
• Clinical talent augmentation: focused hires of new specialists across cardiology, oncology, neurosurgery and allied specialties to raise case-mix complexity and tertiary care share.
• ARPOB uplift from CGHS revision: the revision of CGHS rates for medical procedures is expected to improve average revenue per occupied bed (ARPOB) by approximately 2.5-3.5%.
• Medical tourism focus: enhanced international patient programs and tertiary-specialty offerings are positioned to lift high-value, low-capex revenue.